Development of polymeric micelles for targeting intractable cancers

Cancer Science

Volumn 107, Issue 7, 2016, Pages 867-874

  Nishiyama, Nobuhiro ^a,b   Matsumura, Yasuhiro ^b,c   Kataoka, Kazunori ^b,d,e  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b Innovation Center of NanoMedicine (ICONM)   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clinical trial; drug targeting; nanomedicine; polymeric micelles; theranostics

Indexed keywords

ANTINEOPLASTIC AGENT; COPOLYMER; DRUG CARRIER; POLYMER; POLYMERIC MICELLE; UNCLASSIFIED DRUG;

CLINICAL EVALUATION; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; IN VIVO STUDY; METASTASIS; NEOPLASM; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; REACTION OPTIMIZATION; REVIEW;

EID: 84978795879     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12960     Document Type: Review

References (76)

1. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6: 688–701.
2. Hubbell JA, Langer R. Translating materials design to the clinic. Nat Mater 2013; 12: 963–6.
3. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J Control Release 1993; 24: 119–32.
4. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001; 47: 113–31.
5. Nishiyama N, Kataoka K. Nanostructured devices based on block copolymer assemblies for drug delivery: designing structures for enhanced drug function. Adv Polym Sci 2006; 193: 67–101.
6. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006; 112: 630–48.
7. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev 2009; 61: 768–84.
8. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009; 100: 572–9.
9. Miyata K, Nishiyama N, Kataoka K. Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses. Chem Soc Rev 2012; 41: 2562–74.
10. Cabral H, Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J Control Release 2014; 190: 465–76.
11. Kato KS, Nishiyama N, Kozaki M et al. General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation. J Control Release 2015; 210: 76–83.
12. Yokoyama M, Sugiyama T, Okano T et al. Analysis of micelle formation of an adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer by gel permeation chromatography. Pharm Res 1993; 10: 895–9.
13. Yamamoto Y, Yasugi K, Harada A, Nagasaki Y, Kataoka K. Temperature-related change in the properties relevant to drug delivery of poly(ethylene glycol)-poly(D, L-lactide) block copolymer micelles in aqueous milieu. J Control Release 2002; 82: 359–71.
14. Cabral H, Matsumoto Y, Mizuno K et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011; 6: 815–23.
15. Mochida Y, Cabral H, Miura Y et al. Bundled assembly of helical nanostructures in polymeric micelles loaded with platinum drugs enhancing therapeutic efficiency against pancreatic tumor. ACS Nano 2014; 8: 6724–38.
16. Christie RJ, Matsumoto Y, Miyata K et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 2012; 6: 5174–89.
17. Miura Y, Takenaka T, Toh K et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano 2013; 7: 8583–92.
18. Ahn JY, Miura Y, Yamada N et al. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials 2015; 39: 23–30.
19. Yamamoto Y, Hyodo I, Koga Y et al. Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models. Cancer Sci 2015; 106: 627–34.
20. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995; 16: 195–214.
21. Mosqueria VCF, Legrand P, Gulik A et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanoparticles. Biomaterials 2001; 2001: 2967–79.
22. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387–92.
23. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005; 103: 405–18.
24. Murakami M, Cabral H, Matsumoto Y et al. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med 2011; 3: 64ra2.
25. Harris JM. Introduction to biotechnical and biomedical applications of poly(ethylene glycol) (Ch 1). In: Harris JM, ed. Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications. New York: Plenum, 1992; 1–13.
26. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600–3.
27. Soleymani Abyaneh H, Vakili MR, Zhang F, Choi P, Lavasanifar A. Rationale design of block copolymer micelles to control burst drug release at a nanoscale dimension. Acta Biomater 2015; 24: 127–39.
28. Fonge H, Huang H, Scollard D, Reilly RM, Allen C. Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles. J Control Release 2012; 157: 366–74.
29. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003; 100: 6039–44.
30. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7: 243–54.
31. Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev 2004; 56: 1023–50.
32. Gillies ER, Fréchet JM. A new approach towards acid sensitive copolymer micelles for drug delivery. Chem Commun 2003; 14: 1640–1.
33. Vander H, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–33.
34. Bae Y, Nishiyama N, Fukushima S, Koyama H, Matsumura Y, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem 2005; 16: 122–30.
35. Harada M, Bobe I, Saito H et al. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci 2011; 102: 192–9.
36. Takahashi A, Yamamoto Y, Yasunaga M et al. NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci 2013; 104: 920–5.
37. Nishiyama N, Okazaki S, Cabral H et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003; 63: 8977–83.
38. Cabral H, Nishiyama N, Okazaki S et al. Preparation and biological properties of dichloro(1,2-diaminocyclohexane) platinum (II) loaded polymeric micelles. J Control Release 2005; 101: 223–32.
39. Uchino H, Matsumura Y, Negishi T et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cispatin in rats. Br J Cancer 2005; 93: 678–87.
40. Baba M, Matsumoto Y, Kashio A et al. Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs. J Control Release 2012; 157: 112–17.
41. Cabral H, Murakami M, Hojo H et al. Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc Natl Acad Sci USA 2013; 110: 11397–402.
42. Minko T, Kopeckova P, Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer 2000; 86: 108–17.
43. Katayose S, Kataoka K. Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer. Bioconjug Chem 1997; 8: 702–7.
44. Kataoka K, Togawa H, Harada A, Yasugi K, Matsumoto T, Katayose S. Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in physiological saline. Macromolecules 1996; 29: 8556–7.
45. Lee Y, Kataoka K. Delivery of nucleic acid drugs. Adv Polym Sci 2012; 249: 95–134.
46. Itaka K, Kataoka K. Progress and prospects of polyplex nanomicelles for plasmid DNA delivery. Curr Gene Ther 2011; 11: 457–65.
47. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95: 4607–12.
48. Kano MR, Bae Y, Iwata C et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-signaling. Proc Natl Acad Sci USA 2007; 104: 3460–5.
49. Rafi M, Cabral H, Kano MR et al. Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J Control Release 2012; 159: 189–96.
50. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. New Eng J Med 2003; 348: 2491–9.
51. Cabral H, Makino J, Matsumoto Y et al. Systemic targeting of lymph node metastasis through the blood vascular system by using size-controlled nanocarriers. ACS Nano 2015; 9: 4957–67.
52. Wu H, Cabral H, Toh K et al. Polymeric micelles loaded with platinum anticancer drugs target preangiogenic micrometastatic niches associated with inflammation. J Control Release 2014; 189: 1–10.
53. Groothuis DR. The blood-brain and blood tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000; 2: 45–59.
54. Danhier F, Breton AL, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012; 9: 2961–73.
55. Scaringi C, Minniti G, Caporello P, Enrici RM. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res 2012; 32: 4213–23.
56. Sawant RR, Jhaveri AM, Torchilin VP. Immunomicelles for advancing personalized therapy. Adv Drug Deliv Rev 2012; 64: 1436–46.
57. Noh T, Kook YH, Park C et al. Block copolymer micelles conjugated with anti-EGFR antibody for targeted delivery of anticancer drug. J Polym Sci Pol Chem 2008; 46: 7321–31.
58. Li W, Zhao H, Qian W et al. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 2012; 33: 5349–62.
59. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012; 119: 924–32.
60. Mullard A. Maturing antibody–drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013; 12: 329–32.
61. Lee KS, Chung HC, Im SA et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008; 108: 241–50.
62. Kim DW, Kim SY, Kim HK et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007; 18: 2009–14.
63. Lee JL, Ahn JH, Park SH et al. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs 2012; 30: 1984–90.
64. Kim HS, Lee JY, Lim SH et al. A prospective phase II study of cisplatin and Cremophor EL-free paclitaxel (Genexol-PM) in patients with unresectable thymic epithelial tumors. J Thorac Oncol 2015; 10: 1800–6.
65. Hamaguchi T, Matsumura Y, Suzuki M et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005; 92: 1240–6.
66. Hamaguchi T, Kato K, Yasui H et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007; 97: 170–6.
67. Kato K, Chin K, Yoshikawa K et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs 2012; 30: 1621–7.
68. Plummer R, Wilson RH, Calvert H et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumors. Br J Cancer 2011; 104: 593–8.
69. Su WC, Chen LT, Li CP et al. A novel micellar formulation of cisplatin, in combination with gemcitabine in patients with pancreatic cancer in Asia - Results of Phase I. ESMO 2012; Abstract 863.
70. Seymour LW, Ferry DR, Kerr DJ et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Cancer 2009; 34: 1629–36.
71. Stapleton S, Milosevic M, Allen C et al. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLoS ONE 2013; 8: e81157.
72. Mi P, Kokuryo D, Cabral H et al. Hydrothermally synthesized PEGylated calcium phosphate nanoparticles incorporating Gd-DTPA for contrast enhanced MRI diagnosis of solid tumors. J Control Release 2014; 174: 63–71.
73. Kumagai M, Sarma TK, Cabral H et al. Enhanced in vivo magnetic resonance imaging of tumors by PEGylated iron-oxide-gold core-shell nanoparticles with prolonged blood circulation properties. Macromol Rapid Commun 2010; 31: 1521–8.
74. Kaida S, Cabral H, Kumagai M et al. Visible drug delivery by supramolecular nanocarriers directing to single-platformed diagnosis and therapy of pancreatic tumor model. Cancer Res 2010; 70: 7031–41.
75. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res 2011; 44: 1029–38.
76. Cabral H, Nishiyama N, Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res 2011; 44: 999–1008.